UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE14D-9
(Rule14d-101)
(Amendment No. 1)
Solicitation/Recommendation Statement
Under Section 14(d)(4) of the Securities Exchange Act of 1934
CASCADIAN THERAPEUTICS, INC.
(Name of Subject Company)
CASCADIAN THERAPEUTICS, INC.
(Name of Persons Filing Statement)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
14740B606
(CUSIP Number of Class of Securities)
Scott D. Myers
President and Chief Executive Officer
Cascadian Therapeutics, Inc.
3101 Western Avenue, Suite 600
Seattle, WA 98121
(206)801-2100
(Name, Address, and Telephone Number of Person Authorized To Receive Notices and Communications on Behalf of the Person(s) Filing Statement)
With copies to:
Paul J. Jaskot
Three Logan Square
1717 Arch Street, Suite 3100
Philadelphia, PA 19103
(215)851-8180
| ☐ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
This Amendment No. 1 (this “Amendment”) amends and supplements the Solicitation/Recommendation Statement onSchedule 14D-9 previously filed by Cascadian Therapeutics, Inc., a Delaware corporation (“Cascadian”) with the U.S. Securities and Exchange Commission on February 8, 2018 (together with the exhibits and annexes thereto and as amended and supplemented from time to time, the “Schedule 14D-9”). TheSchedule 14D-9 relates to the tender offer by Valley Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Seattle Genetics, Inc., a Delaware corporation, to purchase all of the outstanding shares of Cascadian’s common stock, par value $0.0001 per share. The information set forth in theSchedule 14D-9 remains unchanged and is incorporated herein by reference, except that such information is hereby amended or supplemented to the extent specifically provided herein.
| Item 9. | Exhibits. |
Item 9 of theSchedule 14D-9 is hereby amended and supplemented by adding the following exhibit:
| (a)(5)(C) | Cascadian Therapeutics Employee FAQs, first used on February 14, 2018 | |
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| Cascadian Therapeutics, Inc. | ||||||
| Dated: February 14, 2018 | By: | /s/ Julia M. Eastland | ||||
| Name: | Julia M. Eastland | |||||
| Title: | Chief Financial Officer and Chief Business Officer | |||||
